https://pharmadevicenews.com/edison-scientific-signs-pfizer-agreement-to-deploy-kosmos-ai-scientist-across-pharmaceutical-rd/ PharmaDeviceNews en 2026-10-30T05:49:11+00:00 Edison Scientific signs Pfizer agreement to deploy Kosmos AI scientist across pharmaceutical R&D Edison Scientific, FutureHouse, Kosmos, Pfizer Inc., Sam Rodriques, San Francisco, Spark Capital, Springer Nature, Triatomic Capital https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp https://pharmadevicenews.com/hsg-has-taken-control-of-peiertech-but-why-is-medical-grade-nitinol-attracting-private-equity-investment/ PharmaDeviceNews en 2026-10-30T05:45:13+00:00 HSG has taken control of PeierTech, but why is medical-grade nitinol attracting private equity investment? Amy Shen, China, HSG, Jiangsu, Jiangyin, PeierTech, Sequoia China, Steve Jia https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Medical-Devices.webp https://pharmadevicenews.com/glooko-reports-no-severe-hypoglycaemia-in-267-patient-endotool-iv-labour-and-delivery-analysis/ PharmaDeviceNews en 2026-10-30T04:10:16+00:00 Glooko reports no severe hypoglycaemia in 267-patient EndoTool IV labour and delivery analysis Advocate Health, Diabetes Technology Society, EndoTool IV, EndoTool IV Cloud, GestationalCare, Glooko Inc., Joseph Aloi, Mark Clements, Mike Alvarez, United States Food and Drug Administration, Wake Forest University School of Medicine https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/ono-pharmaceuticals-ono-1110-missed-three-pain-trial-endpoints-so-why-is-the-drug-still-moving-forward/ PharmaDeviceNews en 2026-10-30T04:01:32+00:00 Ono Pharmaceutical’s ONO-1110 missed three pain trial endpoints, so why is the drug still moving forward? Japan, Ltd., Ono Pharmaceutical Co., ONO-1110, ONO-1110-04, ONO-1110-05, ONO-1110-06, ONO-1110-07, ONO-1110-08, Osaka https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp https://pharmadevicenews.com/pythia-labs-launches-ai-antibody-platform-after-generating-binders-against-15-of-22-therapeutic-targets/ PharmaDeviceNews en 2026-10-30T03:53:25+00:00 Pythia Labs launches AI antibody platform after generating binders against 15 of 22 therapeutic targets CCR8, CXCR4, IL11, Joshua Laniado, Los Angeles, MRGPRX2, Pythia Labs, Pythia-1, San Diego, Todd O. Yeates https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/forlong-biotechnology-doses-first-patient-in-australian-phase-1-trial-of-subcutaneous-fl115/ PharmaDeviceNews en 2026-10-29T03:40:42+00:00 Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115 American Society of Clinical Oncology, Australia, China, Dong Wei, Fbody, FL115, FL116, Forlong Biotechnology, JOINN Biologics, Therapeutic Goods Administration, United States https://pharmadevicenews.com/wp-content/uploads/2026/06/Ranok-Therapeutics-enters-the-KRAS-G12D-spotlight-with-early-clinical-activity-data-e1780405932498.webp https://pharmadevicenews.com/nateras-signatera-genome-separates-bladder-cancer-patients-into-91-81-and-55-survival-groups-but-can-mrd-guide-treatment/ PharmaDeviceNews en 2026-10-29T03:37:06+00:00 Natera’s Signatera Genome separates bladder cancer patients into 91%, 81% and 55% survival groups, but can MRD guide treatment? AstraZeneca, Clarity, ESMO, HER2-CR, IMvigor011, KEYNOTE-B21, MDT-Bridge, Minetta Liu, Natera Inc., Roche, Signatera CDx, Signatera Genome, Thomas Powles, VOLGA https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/neurogene-reports-rapid-mecp2-expression-and-new-gene-regulation-data-for-ngn-401-in-rett-syndrome/ PharmaDeviceNews en 2026-10-29T03:32:50+00:00 Neurogene reports rapid MECP2 expression and new gene regulation data for NGN-401 in Rett syndrome Embolden, ESGCT, EXACT, Hamburg, MECP2, Neurogene Inc., NGN-401, Rachel McMinn, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/Doctor-consultation-e1787168079387.webp